Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) Delayed: 25.08 -0.13 (0.52%)
Previous Close $25.21    52 Week High $37.39 
Open $25.22    52 Week Low $28.25 
Day High $25.31    P/E 15.20 
Day Low $24.96    EPS $1.65 
Volume 41,061,133       

Pfizer Inc. (NYSE: PFE) Delayed: 25.08 -0.13 (0.52%)
Previous Close $25.21    52 Week High $37.39 
Open $25.22    52 Week Low $28.25 
Day High $25.31    P/E 15.20 
Day Low $24.96    EPS $1.65 
Volume 41,061,133       

Sangamo Biosciences, Inc. (NASDAQ: SGMO) Delayed: 0.18 --0 (-0%)
Previous Close $0.18    52 Week High $9.91 
Open $0.18    52 Week Low $3.10 
Day High $0.18    P/E N/A 
Day Low $0.18    EPS $-0.48 
Volume 1,162,512